SEIZURE MANAGEMENT IN PATIENTS WITH PRIMARY AND METASTATIC BRAIN TUMOURS

Effective Date: September, 2014

The recommendations contained in this guideline are a consensus of the Alberta Provincial Central Nervous System Tumour Team and are a synthesis of currently accepted approaches to management, derived from a review of relevant scientific literature. Clinicians applying these guidelines should, in consultation with the patient, use independent medical judgment in the context of individual clinical circumstances to direct care.
BACKGROUND

Seizures are common in patients with brain tumours, and seizure management is an important part of clinical treatment. Thirty to 50 percent of primary brain tumour patients present with an epileptic seizure and 10 to 30 percent develop seizures throughout the course of their disease. The incidence of seizures in patients with metastatic brain tumours ranges from 20 to 35 percent. The frequency of seizures also varies by tumour type. Among patients with primary brain tumours, seizures are more common with low-grade gliomas and other less common tumour types (e.g., dysembryoplastic neuroepithelial tumours and gangliogliomas) compared with high-grade gliomas. In a series of 1028 patients with low- or high-grade intracranial gliomas, the prevalence of epilepsy was 49, 69, and 85 percent for patients with glioblastomas, anaplastic gliomas, and low-grade gliomas, respectively. Meningioma patients may also present with seizures both pre- and post-operatively. In a retrospective review of 626 meningioma patients, 13 percent presented with pre-operative seizures, and 7 percent continued to experience seizures 48 months post-operatively. Aside from tumour type, other seizure risk factors include tumour location (cortical tumour, frontal, temporal, and parietal lobe tumours) and age (> 40 years).

The precise cause of seizures in brain tumour patients is unclear. Van Breemen et al. explain that epileptogenesis in patients with brain tumours is likely multifactorial and caused by different tumour types as well as changes in the properties of tumour-cell membranes that generate action potentials, thus affecting neuronal excitability. Seizures in primary or metastatic brain cancer patients may also be caused by metabolic encephalopathies, opportunistic infections, or side effects of therapy.

Overall, seizures are a significant source of morbidity and mortality in patients with primary and metastatic brain tumours and they require aggressive treatment with antiepileptic drugs (AEDs) or non-pharmacological therapies.

GUIDELINE QUESTIONS

- What is the optimal management of seizures in adult patients with primary or metastatic brain tumours?
- What are the recommended driving guidelines for adult patients with primary or metastatic brain tumours experiencing seizures?

DEVELOPMENT AND REVISION HISTORY

This guideline was reviewed and endorsed by the Alberta Provincial Central Nervous System (CNS) Tumour Team. Members of the Alberta Provincial CNS Tumour Team include medical oncologists, radiation oncologists, neurologists, surgical oncologists, nurses, pathologists, and pharmacists. Evidence was selected and reviewed by a working group comprised of members from the Alberta Provincial CNS Tumour Team and a Knowledge Management Specialist from the Guideline Utilization Resource Unit. A detailed description of the methodology followed during the guideline development process can be found in the Guideline Utilization Resource Unit Handbook.

This guideline was originally developed in July, 2014.
SEARCH STRATEGY

PubMed, MEDLINE, EMBASE, and the Cochrane Database of Systematic Reviews were searched to November 22, 2013 for literature on the management of seizures in patients with primary and metastatic brain tumours. The following search terms were used: brain neoplasms (MeSH [Medical Subject Heading]) AND anticonvulsants (MeSH); results were limited to literature published since 2008, human subjects (19+ years), published in English, clinical trials, controlled clinical trials, guidelines, meta analyses, randomized controlled trials, and systematic reviews. Only studies with equal to or greater than 25 patients were considered for the literature review. Reference lists were scanned for relevant literature.

The Search Standards and Guidelines Evidence (SAGE) directory was also searched from 2008 to 2013 for guidelines on seizure management in patients with primary and metastatic brain tumours, as well as other prominent guideline developer websites.

TARGET POPULATION

The recommendations outlined in this guideline are intended for adults over the age of 18 years with primary or metastatic brain tumours. Different principles may apply to pediatric patients.

RECOMMENDATIONS

Key Points:

- At new seizure onset, clinicians should first consider non-enzyme inducing and non-myelosuppressive AEDs, such as levetiracetam (brand name: Keppra).
- Primary or metastatic brain tumour patients on AEDs must be monitored closely for severe adverse side effects, especially:
  - Stevens-Johnson syndrome, which is a life threatening skin condition and warrants the immediate discontinuation of the AED, and
  - Hepatic toxicity, which is associated with the use of phenytoin and can result in acute liver failure.

1. The management of seizures caused by brain tumours should be individualized.

2. Prophylactic antiepileptic drugs (AEDs) are not recommended in brain tumour patients with no history of seizures. If a surgeon chooses to give prophylactic AEDs perioperatively, then the AED should be gradually discontinued after 1 week from surgery.

3. Brain tumour patients with a history of seizures should receive AED therapy; monotherapy is preferred. The following factors should be taken into consideration when choosing an AED:
   - Adverse side effects
   - Drug interactions
   - Speed of titration
   - Cost/drug coverage
   - Medical/psychiatric comorbidities
   - Organ function
4. The Alberta Provincial CNS Tumour Team recommends the following **non-enzyme inducing AEDs** as first line therapy:

<table>
<thead>
<tr>
<th>AED (Abbreviation); Brand Name</th>
<th>Preferred</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Levetiracetam (LEV); Keppra</td>
</tr>
<tr>
<td></td>
<td>Lamotrigine (LTG); Lamictal</td>
</tr>
<tr>
<td>Other Options</td>
<td>Topiramate (TPM); Topamax</td>
</tr>
<tr>
<td></td>
<td>Valproic acid (VPA)/Divalproex (DVP); Depakene/Epival*</td>
</tr>
<tr>
<td></td>
<td>Clobazam (CLB); Frisium</td>
</tr>
<tr>
<td></td>
<td>Lacosamide (LCM); Vimpat</td>
</tr>
<tr>
<td></td>
<td>Perampanel (PER); Fycompa</td>
</tr>
<tr>
<td></td>
<td>Others as they become available</td>
</tr>
</tbody>
</table>

*Note that VPA/DVP are also enzyme-inhibitors and may increase the levels of certain drugs

Non-enzyme inducing AEDs have been chosen as first line therapy because of the reduced effectiveness of chemotherapeutic agents while on an enzyme inducing AED.

5. The Alberta Provincial CNS Tumour Team recommends the following **enzyme inducing AEDs**, if the non-enzyme inducing AEDs are not a viable option:

- Phenytoin (PHT); brand name: Dilantin, or
- Oxcarbazepine (OXC); brand name: Trileptal, or
- Carbamazepine (CBZ); brand name: Tegretol
  - May be considered if patients don’t respond to other recommended AEDs, taking into consideration myelotoxicity if the patient is receiving, or may in the future receive chemotherapy.
- Others as they become available

6. Brain tumour patients with recurring seizures should be evaluated for all of the following prior to a change in AED therapy:

- Patient compliance
- New drug interactions
- Tumour escalation
- Infections
- Increased edema (consider starting or increasing dexamethasone; see The Use of Dexamethasone in Patients with High Grade Gliomas). Although dexamethasone is not a treatment for seizures, treating edema may decrease seizure frequency.
- Note: serum levels are available for some AEDs; levels may be checked when clinically indicated (see recommendation #7)

Consultation with neurology is recommended if seizures cannot be controlled.

7. Trough serum level measurements are indicated if:

- The patient is experiencing frequent seizures, or
- There are signs of toxicity, or
- Medical adjustments might affect AED levels (e.g., administration of dexamethasone)
• Note: it is preferable to increase the initial agent dose as opposed to adding a new AED

The frequency of serum level measurement is dependent on the half-life of the AED. Serum level measurements are currently available for the following recommended AEDs:
• Carbamazepine
• Clobazam
• Phenytoin
• Phenobarbital
• Valproic acid

Please note that this list may change. To obtain the most current information, including therapeutic ranges, please consult the websites of Calgary Laboratory Services or DynaLIFE Dx.

8. Other AED treatment options for recurring seizures include:
• Optimizing the initial agent dose as tolerated and needed, or
• Prescribing an alternative AED, if the initial agent is not tolerated, or
• Adding-on another AED, such as CLB or other agents at the discretion of the treating clinician, or
• Patients who experience auras may be prescribed an AED, such as Lorazepam (1–2mg s.1 pm), to abort a seizure before it starts. This may be particularly effective for patients who find higher doses of AEDs difficult to tolerate.

9. Non-pharmacological treatment options for recurring seizures include:
• Resection of the brain tumour or seizure focus, or
• Radiation therapy (RT), including radiosurgery, or stereotactic brachytherapy, or teletherapy, or fractionated radiation therapy

10. AED therapy should stay the same unless there is a change in clinical status.

Driving Guidelines

11. Patients with uncontrolled seizures must not drive.

12. In Alberta, drivers must report a seizure disorder to Alberta Transportation; physician reporting is discretionary, not mandatory. However, it is recommended that patients who hold a professional license (Class 1–4) be reported. Patients should also be advised to notify their insurance company of their seizure status.

13. The Alberta Provincial CNS Tumour Team members extrapolated from the CMA guidelines for patients driving with epilepsy, and recommend that a patient may be eligible to drive with a Class 5 license after they have been seizure free for 6 months. For brain tumour patients, Alberta Transportation also generally requires that the brain tumour be stable. The Alberta Transportation Guidelines for Return to Driving can be found online and are based on the Canadian Council of Motor Transport Administrators standards. Patients must receive approval from Alberta Transportation to drive.

14. If a patient is driving, then it is strongly recommended they continue taking AEDs.
• Exception: patients with a surgically-curable tumour (e.g., some grade I tumours) who are seizure free for > 1 year may be considered for AED withdrawal.

DISCUSSION

Despite the frequency of seizures in patients with brain tumours, prospective studies on the medical treatment of seizures in this population are scarce. Furthermore, existing studies have limitations, such as being retrospective with small patient numbers and heterogeneous regarding patient characteristics.

Seizure management in patients with brain tumours needs a multidisciplinary approach and should be individualized, taking into consideration a number of different patient-centred factors. Although the use of AEDs is the most common form of seizure management in this patient population, non-pharmacological therapies, such as surgery or RT, may also be considered.

AED Therapy

Brain tumour patients who have experienced a seizure should be treated with a standard first-line AED monotherapy. In the last two decades, several new AEDs have been approved for use in patients with epilepsy; however, clinicians still commonly prescribe the older AEDs. The most common older drugs used in Alberta are: PHT, and CBZ, as well as VPA in patients who have a rash. The newer drugs used in Alberta are: LTG, TPM, LEV, OXC, CLB, and LCM. Unfortunately, there is a lack of large prospective studies and randomized trials comparing the efficacy of old versus new AEDs, specifically in the brain tumour patient population, and therefore, the superiority of one agent over others has not been established. In general, findings from the literature suggest that newer AEDs are better tolerated than older AEDs. However, newer AEDs are also more expensive than the older drugs. Given the inconclusive state of the evidence, clinicians should take into consideration the following factors when choosing an AED: adverse side effects, drug interactions, speed of titration, cost/drug coverage, medical/psychiatric comorbidities, and organ function.

Non-enzyme inducing AEDs. Many AEDs have significant effects on the cytochrome P450 system, which may increase the metabolism of numerous chemotherapeutic agents and supportive care agents, such as dexamethasone. As a result, AEDs that induce the P450 system can significantly reduce serum levels of antitumour agents. Given these clinically significant drug interactions, the National Comprehensive Cancer Network suggest the use of non-enzyme inducing AEDs, where possible, over the use of enzyme inducing AEDs. The Alberta Provincial CNS Tumour Team recommends the following non-enzyme inducing AEDs: LEV, or LTG, or TPM, or VPA, or CLB, or LCM, or PER.

A prospective observational study of 176 glioma patients evaluated the efficacy and safety of LEV in the management of seizures. Eighty-two patients (47 percent) received LEV at a dose that ranged from 1500 to 3000 mg/day; 9 patients required an increase in dosage to 4000 mg/day to become seizure free. At the last evaluation, 91 percent were seizure free (2 of these patients discontinued the drug because of intolerable side effects). The authors of the study concluded that LEV is efficacious and safe in patients with seizures due to glioma.

Maschio and colleagues conducted a prospective observational study to investigate the efficacy and tolerability of TPM in brain tumour patients with seizures (n=47). Follow-up ranged from 3 to 48 months (mean 16.5 months) and at final follow-up 56 percent were seizure free, 20 percent had a seizure
frequency reduction higher than 50 percent and 24 percent were stable. The response rate to TPM was 76 percent; 3 patients discontinued the drug due to severe side effects.

Aside from controlling seizures, Guthrie et al. also found that VPA may improve the survival of patients with glioblastoma. A retrospective cohort of 236 glioblastoma patients (1-year survival 26 percent) received either VPA, another AED, or no AED. The authors of the study found that patients treated with VPA had significantly longer survival than those who did not receive an AED (Mantel-Cox log-rank test 17.506, p<0.001), and patients treated with VPA specifically had a significantly longer survival than those who received other AEDs (Mantel-Cox log-rank test 5.303, p<0.02).

A randomized phase II trial investigated the safety and feasibility of switching from PHT (an enzyme inducing AED) to LEV monotherapy for postoperative control of glioma-related seizures. 20 patients were randomized to receive LEV and 9 patients were randomized to continue receiving PHT. At 6 months follow-up, 87 percent of patients receiving LEV and 75 percent of patients receiving PHT were seizure free. Reported side effects at 6 months were the following (percent LEV/percent PHT): dizziness (0/14), difficulty with coordination (0/29), depression (7/14) lack of energy or strength (20/43), insomnia (40/43), and mood instability (7/0). The results of this phase II study suggest that it is safe to switch patients from PHT to LEV monotherapy following craniotomy for supratentorial glioma.

**Enzyme inducing AEDs.** Although enzyme inducing AEDs increase the metabolism of concurrent chemotherapeutic agents, it is unclear whether this impacts patient outcomes. In particular two studies compared the use of enzyme inducing AEDs to non-enzyme inducing AEDs and reported conflicting results in the glioblastoma patient population. Oberndorfer et al. retrospectively analyzed survival in 168 glioblastoma patients treated with either no AED (n=88), an enzyme inducing AED (n=43), or a non-enzyme inducing AED (n=37). CBZ (81 percent) was the most frequently administered enzyme inducing AED; VPA (85 percent) was the most frequently administered non-enzyme inducing AED. The authors of the study found a significant difference in survival between the two groups; those patients who received a non-enzyme inducing AED survived 13.9 months compared to 10.8 months in the enzyme inducing AED group. The authors conclude that it is uncertain whether the difference in survival is due to a decrease of efficacy of chemotherapeutic agents by the enzyme inducing AED, or to increased efficacy of chemotherapeutic agents caused by the enzyme inhibiting properties of VPA. VPA has been shown to prolong survival in patients receiving temozolomide and RT. Conversely, in a similar study of 620 newly diagnosed glioblastoma patients Jaeckle et al. found that the median overall survival was longer for patients who received an enzyme inducing AED compared with a non-enzyme inducing AED (12.3 versus 10.7 months, p=0.0002). The study authors suggest that in comparative clinical trials that test agents metabolized by the P450 system, treatment arms may need stratification for the proportion of patients receiving enzyme inducing AEDs.

A retrospective observational study of 70 brain tumour patients found that OXC showed a similar efficacy to VPA, a non-enzyme inducing AED, as well as other older enzyme inducing AEDs (CBZ, PB, and PHT). However, the older AEDs had significantly more side effects, both serious and non-serious. Similarly, a prospective observational study of 70 patients with brain metastases found that OXC was equally as effective as LEV and TPM, significantly reducing seizure frequency and producing few side effects. A prospective, randomized, single-centre study of 81 patients found that both LEV (n=36) and PHT (n=38) are well-tolerated perioperatively. Given the inconclusive evidence on the impact of enzyme inducing AEDs on patient outcomes and the common prescription of these drugs by clinicians, the Alberta Provincial CNS Tumour Team recommends the following enzyme inducing AEDs as an alternative to non-enzyme inducing AEDs: PHT, or OXC. CBZ
may be considered if patients don’t respond to other recommended AEDs, taking into consideration myelotoxicity if the patient is receiving, or may in the future receive chemotherapy.

**Prophylactic AEDs.** There is general consensus amongst a number of guideline developers that AED therapy in patients without a history of seizures is not recommended because of a lack of efficacy and the potential for serious side effects.6,17-21 Despite the recommendations, many clinicians still prescribe prophylactic AEDs, and this is particularly true for prophylactic AEDs that are given perioperatively. A survey of 386 neurosurgeons found that more than 70 percent of respondents reported routine use of AED prophylaxis for patients with primary or metastatic brain tumours.22 Given this reality, the Alberta Provincial CNS Tumour Team recommend that if a clinician chooses to give prophylactic AEDs perioperatively, then the AED should be discontinued after 1 week from surgery as quickly and safely as possible, which is in agreement with the American Academy of Neurology recommendation.21

Several observational studies and small randomized trials have shown a lower risk of early postoperative seizures in patients treated with prophylactic AEDs perioperatively.23-25 Lwu et al. present Alberta-specific retrospective data on the use of perioperative AEDs in patients with newly diagnosed high-grade glioma.24 In their study, 27 percent of patients were given prophylactic AEDs and of these, none experienced perioperative seizures (within 1 week). Perioperative seizures occurred in two patients without prophylactic AEDs. Of those patients taking AED prophylaxis, 18 percent were continued on the drug beyond the first perioperative week, which contradicts the American Academy of Neurology guidelines. The authors suggest that increased awareness of practice guidelines may help modify AED prescription patterns in brain tumour patients.

Wu et al. conducted a prospective randomized trial of perioperative seizure prophylaxis in patients with primary (n=46) or metastatic (n=77) brain tumours.26 62 patients received 7-day PHT and 61 patients received no prophylactic AED. The incidence of seizures was 18 percent versus 24 percent (p=0.51), in the observation and prophylaxis group, respectively. The prophylaxis group also experienced significantly more adverse events (18 percent versus 0 percent, p<0.01). In this trial, the incidence of clinically significant seizures was only 3 percent. As a result of these findings, the study authors conclude that the routine use of prophylactic PHT in brain tumour patients is concerning. Similarly, a retrospective cohort study to assess the effectiveness of perioperative seizure prophylaxis (LEV) in high-grade glioma patients found that LEV prophylaxis was not a significant predictor of seizure occurrence; younger age, however, was a significant predictor of greater seizure occurrence.27

A meta-analysis of randomized controlled trials evaluated the efficacy of AED prophylaxis versus no treatment or placebo in patients with brain tumours and found no evidence to support the administration of prophylactic AEDs (PB, PHT, or VPA).28 Similarly, a systematic analysis of the efficacy of prophylactic AEDs across 19 studies found that there were no significant differences in the extent of resection, perioperative mortality, or recurrence between the AED and non-AED cohorts.29 The study authors conclude that prophylactic administration of AEDs during resection provide no benefit in the prevention of either early or late postoperative seizures. A recent Cochrane review of AEDs as prophylaxis for post-craniotomy seizures also concluded that there is little evidence to suggest that AED treatment administered prophylactically is effective in preventing post-craniotomy seizures.30 An older Cochrane review concluded that the decision to start an AED for seizure prophylaxis should ultimately be guided by assessment of individual risk factors and careful discussion with patients regarding predicted risk of seizure, which tends to be low,31 cost, and potential side effects.32
Recurring seizures. The efficacy of AEDs in neuro-oncologic patients is dependent on a number of variables; approximately 60 to 70 percent of patients will experience recurrent seizures. Wick et al. reported that in their study, 70, 51, and 44 percent of patients on CBZ, PHT, and VPA, respectively, had recurrent seizures. It is important to investigate the cause of recurrence prior to a change in AED therapy. The Alberta Provincial CNS Tumour Team recommends that clinicians evaluate the following as potential causes of recurrence: patient compliance, new drug interactions, tumour escalation, and infections. If possible, serum level concentrations may also be verified before prescribing an alternative AED or adding a second agent.

If a patient is experiencing recurrent seizures, the first treatment option is to optimize the initial agent dose as tolerated and needed. Table 1 below provides the minimum and maximum daily doses for the old and newer AEDs, although it should be noted that there are many possibilities and variables to consider when escalating the initial dose.

Table 1. Minimum and Maximum Daily Doses for AEDs*

<table>
<thead>
<tr>
<th>AED (Brand Name)</th>
<th>Daily Dose Range (mg)**</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phenytoin (Dilantin)</td>
<td>200–600</td>
<td>Either at hs or split bid</td>
</tr>
<tr>
<td>Carbamazepine (Tegretol)</td>
<td>200–800</td>
<td>bid; CR preparation</td>
</tr>
<tr>
<td>Valproic acid/Divalprox (Depakene/Epival)</td>
<td>250–1000</td>
<td>bid</td>
</tr>
<tr>
<td>Phenobarbital (Luminal)</td>
<td>30–90</td>
<td>Once or twice a day</td>
</tr>
<tr>
<td>Clobazam (Frisium)</td>
<td>10–40</td>
<td>Either at hs or split bid</td>
</tr>
<tr>
<td>Levetiracetam (Keppra)</td>
<td>250–1500</td>
<td>bid</td>
</tr>
<tr>
<td>Lamotrigine (Lamictal)</td>
<td>100–300</td>
<td>bid; strict titration guidelines</td>
</tr>
<tr>
<td>Topiramate (Topamax)</td>
<td>50–250</td>
<td>bid</td>
</tr>
<tr>
<td>Oxcarbazepine (Trileptal)</td>
<td>150–450</td>
<td>bid</td>
</tr>
<tr>
<td>Lacosamide (Vimpat)</td>
<td>100–200</td>
<td>bid</td>
</tr>
</tbody>
</table>

*More detailed information about initial doses, rate of dose increase, usual seizure dose range, and maximum dose in the drug charts can be found on the RxFiles website (institutional subscription may be required).**The maximum dose is typically determined by patient side-effects.

If a patient continues to experience recurrent seizures and the initial agent is not tolerated, then the clinician should either prescribe an alternative AED or add-on another AED, such as CLB or any other agent at the discretion of the treating clinician. Patients who experience auras may be prescribed an AED, such as Lorazepam (1–2mg s.1 pm), to abort a seizure before it starts. This may be particularly effective for patients who find higher doses of AEDs difficult to tolerate.

A recent retrospective analysis was performed on 181 glioblastoma patients with seizures to examine the efficacy of VPA given either with or without LEV on seizure control and survival. At the end of follow-up (minimum 6 months), 78 percent of patients on VPA and 70 percent of patients on LEV were seizure free with monotherapy. Of those patients with recurrent seizures who received polytherapy with VPA and LEV, 60 percent achieved seizure freedom. Patients on VPA and temozolomide had a median survival of 69 weeks compared to 61 weeks in the group without VPA after adjusting for various factors. The authors of the study conclude that polytherapy with VPA and temozolomide more strongly contributes to seizure control than does either as monotherapy.

Another retrospective observational study of 140 brain tumour patients (99 with seizures), of whom 24 percent had a low-grade glioma, 54 percent had a high-grade glioma, and 23 percent had either ependymoma, meningioma, or brain metastasis, found that patients treated with a combination of VPA...
and LEV showed the highest percentage of responders (82 percent) compared to other AED monotherapy. In this group 59 percent of patients achieved seizure freedom. The authors of the study suggest that rather than administering sequential trials of AED monotherapy, add-on LEV might be more effective than VPA alone or LEV alone.

Several studies have assessed LEV as an add-on treatment and found that it is well tolerated. One prospective study and two retrospective studies found that the rate of response to add-on LEV ranges between 65 and 90 percent and the percentage of seizure free patients ranges from 20 to 59 percent. A small prospective study of add-on gabapentin found that 100 percent of patients had seizure reduction and 57 percent achieved seizure freedom. It should be noted that all of these studies are limited by small sample sizes and heterogeneous patient tumour characteristics.

Unfortunately, certain brain tumour patients are resistant to AEDs and will continue to experience seizures despite the use of AEDs and adequate serum concentrations. Ruda et al. explain that the major cause of resistance to AEDs is over-expression of proteins belonging to the ATP-binding cassette transporter family, which have been reported in tumour cells of glioma patients, and can lead to diminished drug transport into the brain parenchyma. AEDs may also fail to control seizures because of a loss of receptor sensitivity. For these patients, it is important to consider non-pharmacological treatment therapies to manage recurrent seizures (please see Non-pharmacological Treatment section below).

### Adverse Side Effects of AEDs

AEDs can have serious side effects that may affect a patient’s quality of life. Brain tumour patients also experience a higher incidence of adverse effects, ranging from 30 to 40 percent, than that observed in seizure patients without brain tumours. Of those brain tumour patients that experience adverse effects as a result of AEDs, 24 percent are severe enough to warrant a change or discontinuation of AED therapy.

#### Common side effects. The most common side effects of AEDs recommended by the Alberta Provincial CNS Tumour Team are listed in Table 2 below. Cognitive impairment, bone-marrow suppression, liver dysfunction, and dermatological reactions are some of the more commonly experienced side effects of AEDs. Long term therapy with the older AEDs can also have an adverse effect on bone metabolism, which is pertinent for low grade glioma patients.

#### Mild skin rashes. Mild skin rashes are frequently observed in patients taking AEDs; brain tumour patients compared to those without have a higher likelihood of drug rash with AEDs. A retrospective review of 289 patients that received RT found that 18 percent experienced mild rashes, compared with the expected rate of 5 to 10 percent. The study authors noted that mild drug rashes among brain tumour patients did not appear to be related to RT. Cross-sensitivity rash has also been reported between various AEDs, such as PHT, PB, CBZ, OXC, and LTG, especially between CBZ and PHT. Arif et al. investigated predictors of AED-related rash in 1,890 patients and found that the risk of developing a rash increased three- to four-fold if the patient had a rash to one or more AED, or an allergy to another medication.
Table 2. Common Systemic and Neurotoxic Side Effects of AEDs

<table>
<thead>
<tr>
<th>AED</th>
<th>Systemic Side Effects</th>
<th>Neurotoxic Side Effects</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>CBZ</td>
<td>Nausea, vomiting, diarrhea, hyponatremia, rash, pruritus, weight gain</td>
<td>Drowsiness, dizziness, blurred or double vision, lethargy, headache, ataxia</td>
<td>Need to monitor CBC, electrolytes and LFTs</td>
</tr>
<tr>
<td>CLB</td>
<td>Increased salivation, nausea, vomiting, constipation, weight gain</td>
<td>Somnolence, aggression, irritability, ataxia, insomnia</td>
<td>Side effects are very uncommon</td>
</tr>
<tr>
<td>LTG</td>
<td>Rash, nausea</td>
<td>Dizziness, tremor, diplopia</td>
<td></td>
</tr>
<tr>
<td>LEV</td>
<td>Infection*</td>
<td>Fatigue, somnolence, dizziness, agitation, anxiety, irritability, depression</td>
<td>*Infection is uncommon</td>
</tr>
<tr>
<td>OXC</td>
<td>Nausea, rash, hyponatremia</td>
<td>Sedation, headache, dizziness, vertigo, ataxia, diplopia</td>
<td>Need to monitor CBC, electrolytes and LFTs</td>
</tr>
<tr>
<td>PHT</td>
<td>Gingival hypertrophy, rash</td>
<td>Confusion, slurred speech, double vision, ataxia</td>
<td>Need to monitor CBC and LFTs</td>
</tr>
<tr>
<td>TPM</td>
<td>Weight loss, paresthesias</td>
<td>Fatigue, nervousness, difficulty concentrating, confusion, depression, anorexia, language problems, anxiety, mood problems</td>
<td>Avoid if patient has a history of kidney stones</td>
</tr>
<tr>
<td>VPA</td>
<td>Weight gain, nausea, vomiting, hair loss, easy bruising, low platelets</td>
<td>Tremor, dizziness</td>
<td>Need to monitor CBC and LFTs</td>
</tr>
</tbody>
</table>

Stevens-Johnson syndrome. Severe skin reactions, such as Stevens-Johnson syndrome, may occur in a small percentage of patients during the first 4–8 weeks on CBZ, PB, PHT, or LTG, especially in patients who have received cranial RT. Patients who exhibit signs of Stevens-Johnson syndrome must discontinue the use of the AED immediately.

Chemotherapeutic drug interactions. In addition to direct adverse side effects, some AEDs also have clinically significant interactions with chemotherapeutic agents used to treat brain tumour patients. As previously mentioned, the enzyme inducing AEDs, such as PHT, CBZ, and OXC, may significantly reduce serum levels of chemotherapeutic agents, including nitrosoureas, cyclophosphamide, ifosfamide, procarbazine, vincristine, paclitaxel, irinotecan, topotecan, 9-aminoacamphtetecin, doxorubicin, teniposide, thiotepa, methotrexate, and busulfan. In addition, certain chemotherapeutic agents, such as methotrexate, doxorubicin, adriamycin, and cisplatin have been shown to decrease serum levels of VPA, CBZ, and PHT, as well. Fortunately, the most common chemotherapeutic agent used to treat brain tumour patients, temozolomide, has no clinically significant drug interactions with AEDs.

Other drug interactions. AEDs may also interact with the metabolism of various steroids, including cortisol, prednisone, and dexamethasone, which is commonly used in brain tumour patients to control peritumoral edema. For example, PHT induces the hepatic metabolism of dexamethasone, reducing its half-life and bioavailability. VPA, specifically, has distinct enzyme-inhibiting properties, which may reduce the metabolism of another drug by raising plasma concentrations. This may result in an increase in bone marrow toxic effects of concomitant chemotherapeutic agents.

Cognitive function. Several AEDs also significantly impact the patient’s cognitive function and quality of life. Klein et al. compared 156 patients with low-grade gliomas and seizures to healthy controls. Compared with the healthy controls, glioma patients had significant reductions in information processing speed, psychomotor function, attentional functioning, verbal and working memory, executive functioning, and health-related quality of life, most of which were attributed to the use of AEDs.
Generally speaking, newer AEDs that are non-enzyme inducing have significant advantages over older agents when it comes to adverse side effects.

Non-pharmacological Treatment

As previously mentioned, some patients are resistant to AED therapy and in these cases, non-pharmacological treatment approaches should be considered.

Surgery. Tumor resection may remove the seizure focus and therefore control seizures. However, the seizure focus in brain tumor patients may be located outside the main tumor mass and in this situation even a gross total resection will not control the seizures. The percentage of seizure free patients after tumor surgery ranges from 65 to 82 percent; the most significant prognostic factors associated with seizure freedom are completeness of tumor resection and short preoperative duration of tumour-associated seizures. Englot et al. conducted a systematic review of seizure outcomes after surgical resection of low-grade brain tumours in 910 patients from 39 studies. The study authors found that 80 percent of patients were seizure free after surgery. Higher rates of seizure freedom were achieved in patients with ≤1 year duration of seizures compared to patients with >1 year of seizures (OR 9.48, 95 percent CI 2.26–39.66) and in patients with gross-total resection compared to subtotal lesionectomy (OR 5.34, 95 percent CI 3.61–7.89). Similarly, a retrospective study of 269 patients with low-grade gliomas who underwent initial surgery found that 89 percent of patients were seizure free at 6 months following gross total resection versus 57 percent following subtotal resection. Van Breemen et al. note that in the majority of series reporting high rates of seizure freedom after surgery, the epileptogenic zone was excised together with the tumour, whereas general surgery for brain tumours typically resects part or all of the tumour without special attention to the epileptogenic zone.

Radiation therapy. There is limited data on the effect of RT on tumour-related seizures, although some studies have found that RT can result in improved seizure control. A phase III trial compared 157 patients receiving adjuvant postoperative RT (54 Gy in fractions of 1.8 Gy) versus observation (n=157) in low-grade glioma patients and found that at 1 year, 25 percent of RT patients had seizures compared to 41 percent in the observation group. In a retrospective study of 43 glioma patients with medically intractable seizures, 76 percent of patients achieved a significant reduction in seizures and 32 percent were seizure free at 12 months following RT. The study authors observed that seizure reduction occurred more often in patients displaying an objective tumour response on MRI; however, patients with no change on MRI also had a significant seizure reduction, suggesting that ionizing radiation on seizure control include damage to epileptogenic neurons or metabolic changes of the microenvironment. The study authors also found that timing of RT and duration of seizures prior to RT was significantly associated with seizure reduction.

Driving Guidelines

The Alberta Provincial CNS Tumour Team recommends that patients with uncontrolled seizures not drive. Patients with brain tumours who have not had a seizure and who are driving should not be placed on prophylactic AEDs. In Alberta, drivers are required by law to report any health condition, including seizures, that may affect their ability to drive safely; physician reporting to Alberta Transportation is discretionary, not mandatory. However, if a patient has been instructed not to drive, it is important to document this in their medical record. Patients should be advised of the risk of seizure activity and the
potential for driving restrictions that may occur while on AEDs. Patients are also required to advise their insurance company of their condition to ensure that their policy is valid in the event of an accident.

In accordance with the CMA guidelines for driving with epilepsy, a patient may be eligible to drive with a Class 5 license after they have been seizure free for 6 months and with a favourable recommendation from their treating clinician. However, the CMA suggests that each case be evaluated individually by the treating clinician(s). Patients may obtain more information about the license reinstatement process from Alberta Transportation, Driver Fitness & Monitoring Department at (780) 427-8230 or [link](http://www.transportation.alberta.ca/542.htm).

**Follow-up & Surveillance**

The Alberta Provincial CNS Tumour Team recommends that AED therapy stay the same unless there is a change in clinical status. The continuation of AEDs is recommended because of the absence of data for seizure outcome after withdrawal, and high seizure recurrence in adults. To add, if a patient is driving, then they are strongly recommended to continue taking AEDs due to the high risk of fatal outcomes if a seizure were to recur. The exception to AED withdrawal is for patients with a surgically-curable tumour, such as some grade I tumours, who are seizure free for > 1 year; in this patient population, AED withdrawal may be considered. These patients still have a risk of seizures 6 months post-surgery, and there is minimal evidence between the 6 month to 1 year range; therefore, most experts agree that AEDs may be weaned 1 year post-surgery.
TREATMENT ALGORITHM

Given the inconclusive evidence on seizure management for brain tumour patients, treatment should be individualized.

Primary or Metastatic Brain Tumour

If perioperative prophylactic AED administered?

Yes

Perioperative AEDs are NOT recommended

No

Seizure History?

Yes

AED Therapy

Choice of AED is dependent on:
• Adverse side effects
• Drug interactions
• Speed of titration
• Cost/drug coverage
• Medical/psychiatric comorbidities
• Organ function

No

AED Therapy

Choice of AED is dependent on:
• Adverse side effects
• Drug interactions
• Speed of titration
• Cost/drug coverage
• Medical/psychiatric comorbidities
• Organ function

Discontinue after 1 week from surgery if patient is medically stable and/or experiencing severe AED-related side effects

Preferred Monotherapy First-Line Non-Enzyme Inducing AEDs:
• Levetiracetam, or
• Lamotrigine, or

Other Option Monotherapy First-Line Non-Enzyme Inducing AEDs:
• Topiramate, or
• Valproic acid, or
• Gabapentin, or
• Lacosamide, or
• Perampanel, or
• Others as they become available

Enzyme Inducing AEDs**, if the first-line AEDs are not a viable option:
• Phenytoin, or
• Oxcarbazepine, or
• Carbamazepine (note possible myelotoxicity), or
• Others as they become available

*Driving Restrictions

• Patients with uncontrolled seizures must not drive.
• In Alberta, drivers must report a seizure disorder to Alberta Transportation; physician reporting is discretionary, not mandatory. It is recommended that patients who hold a professional license (Class 1–4) be reported.
• Extrapolating from the CMA guidelines, a patient may be eligible to drive with a Class 5 license after they have been seizure free for 6 months. Patients must receive approval from Alberta Transportation.

Follow-up & Surveillance

• If a patient is driving, then it is strongly recommended they continue taking AEDs
• Exception: Patients with a surgically-curable tumour (e.g., some grade I tumours) who are seizure free for > 1 year may be considered for AED withdrawal
• AED therapy should stay the same unless there is a change in clinical status
• ***Serum levels are available for some AEDs; levels can be checked when clinically indicated (please see recommendations in text)

No

Recurrence of Seizure?

Yes

Optimize initial agent dose as tolerated and needed

Prescribe alternative AED, if initial agent not tolerated, or
Add-on Non-Enzyme Inducing AEDs:
• Clobazam, or
• Other agents at the discretion of the treating clinician, or
Prescribe an AED, such as Lorazepam, for patients with auras

Non-pharmacological Therapies

Surgery

Resection of brain tumour or seizure focus

Radiation Therapy

• Radiosurgery, or
• Stereotactic brachytherapy, or
• Teletherapy, or
• Fractionated radiation therapy

Institute cause of recurrence:
• Patient compliance?
• New drug interactions?
• Tumour escalation?
• Infections?
• Increased edema?

Verify serum concentrations, if possible***

Repeat Follow-up & Surveillance

*Driving Restrictions

• Patients with uncontrolled seizures must not drive.
• In Alberta, drivers must report a seizure disorder to Alberta Transportation; physician reporting is discretionary, not mandatory. It is recommended that patients who hold a professional license (Class 1–4) be reported.
• Extrapolating from the CMA guidelines, a patient may be eligible to drive with a Class 5 license after they have been seizure free for 6 months. Patients must receive approval from Alberta Transportation.

Yes

Repeat Follow-up & Surveillance

www.albertahealthservices.ca
GLOSSARY OF ABBREVIATIONS

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AED</td>
<td>Antiepileptic drug</td>
</tr>
<tr>
<td>CBZ</td>
<td>Carbamazepine</td>
</tr>
<tr>
<td>CI</td>
<td>Confidence interval</td>
</tr>
<tr>
<td>CLB</td>
<td>Clobazam</td>
</tr>
<tr>
<td>CMA</td>
<td>Canadian Medical Association</td>
</tr>
<tr>
<td>CNS</td>
<td>Central nervous system</td>
</tr>
<tr>
<td>LCM</td>
<td>Lacosamide</td>
</tr>
<tr>
<td>LEV</td>
<td>Levetiracetam</td>
</tr>
<tr>
<td>LTG</td>
<td>Lamotrigine</td>
</tr>
<tr>
<td>OR</td>
<td>Odds ratio</td>
</tr>
<tr>
<td>OXC</td>
<td>Oxcarbazepine</td>
</tr>
<tr>
<td>PB</td>
<td>Phenobarbital</td>
</tr>
<tr>
<td>PER</td>
<td>Perampanel</td>
</tr>
<tr>
<td>PHT</td>
<td>Phenytoin</td>
</tr>
<tr>
<td>RT</td>
<td>Radiation therapy</td>
</tr>
<tr>
<td>TPM</td>
<td>Topiramate</td>
</tr>
<tr>
<td>VPA</td>
<td>Valproic acid</td>
</tr>
</tbody>
</table>

DISSEMINATION

- Present the guideline at the local and provincial tumour team meetings and weekly rounds.
- Post the guideline on the Alberta Health Services website.
- Send an electronic notification of the new guideline to all members of CancerControl Alberta.

MAINTENANCE

A formal review of the guideline will be conducted at the Annual Provincial Meeting in 2016. If critical new evidence is brought forward before that time, however, the guideline working group members will revise and update the document accordingly.

CONFLICT OF INTEREST

Participation of members of the Alberta Provincial CNS Tumour Team in the development of this guideline has been voluntary and the authors have not been remunerated for their contributions. There was no direct industry involvement in the development or dissemination of this guideline. CancerControl Alberta recognizes that although industry support of research, education and other areas is necessary in order to advance patient care, such support may lead to potential conflicts of interest. Some members of the Alberta Provincial CNS Tumour Team are involved in research funded by industry or have other such potential conflicts of interest. However the developers of this guideline are satisfied it was developed in an unbiased manner.
REFERENCES